Enrichment factors for clinical trials in mild-to-moderate Alzheimer's disease

Heterogeneity of outcomes in Alzheimer's disease (AD) clinical trials necessitates large sample sizes and contributes to study failures. This analysis determined whether mild-to-moderate AD populations could be enriched for cognitive decline based on apolipoprotein (APOE) ε4 genotype, family history of AD, and amyloid abnormalities.This article is freely available via Open Access. Click on the Publisher's URL to access the full text